<DOC>
	<DOCNO>NCT00558493</DOCNO>
	<brief_summary>A multi-center open study compare safety effectiveness switch treatment lamivudine clevudine 24 week .</brief_summary>
	<brief_title>Switching Study From Lamivudine Clevudine Chronic Hepatitis B Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Clevudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>HBV DNA &gt; 2,000 copies/mL screen Patients compensate liver disease ( ChildPugh score = &lt; 6 ) Patients without LMV resistant mutation RFMP assay Patients NOT experienced viral breakthrough consecutive two measurement ( least one month apart ) lamivudine monotherapy Patients submit write consent comply claim postulate clinical trial Currently receive antiviral except LMV corticosteroid therapy Patients previously receive antiviral treatment hepatitis B lamivudine proceed 12 month Previous treatment interferon immunomodulatory therapy must end least 6 month precede study screen Treatment nephrotoxic drug , competitor renal excretion , and/or hepatotoxic drug within 2 month study screen study period Patients coinfected HCV , HDV HIV Serious concurrent medical condition Prior organ transplantation Patient creatinine clearance le 60mL/min estimate follow formula : [ ( 140age year ) ( body weight [ kg ] ) ] / [ ( 72 ) ( serum creatinine ] [ mg/dL ] ) [ Note : multiply estimate 0.85 woman ]</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>